Interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) have an array
of immunomodulatory treatment options compared with IPF, due to their inflammatory …

Patient-reported outcome measures (PROMs), tools to assess patient self-report of health
status, are now increasingly used in research, care and policymaking. While there are two …

Background: Multiple sclerosis (MS) is a chronic neurodegenerative disease. Current
monitoring practices predominantly rely on brief and infrequent assessments, which may not …

Background Transthyretin amyloidosis, or ATTR, is a progressive and debilitating rare
proteopathy generally manifested as either transthyretin amyloid polyneuropathy (ATTR-PN) …

Rationale: Patients with idiopathic pulmonary fibrosis (IPF) and their caregivers experience
stress, symptom burden, poor quality of life, and inadequate preparedness for end-of-life …

Background The serum creatinine/cystatin C (Cr/CysC) ratio has attracted attention as a
marker for sarcopenia, but has not been studied in patients with idiopathic pulmonary …

Aims Patients diagnosed with idiopathic pulmonary fibrosis (IPF) have a high symptom
burden and numerous needs that remain largely unaddressed despite advances in …

Objectives Sarcopenia is a syndrome characterized by reduced muscle mass and function. It
is well-recognized as a complication in chronic diseases such as chronic obstructive …

Idiopathic pulmonary fibrosis (IPF), an incurable lung disease of unknown cause, often
presents with losses of skeletal muscle mass. IPF requires comprehensive care, but it has …

Pulmonary fibrosis is a progressive and fatal fibrotic lung disease and associated with a high
mortality rate. In the study, the prevention and treatment effects of fibroblast growth factor-21 …